Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study

Abstract

Lymphoma can be treated with autologous hematopoietic stem cell transplantation. The mobilization and collection of hematopoietic stem cells is essential for the success of stem cell transplantation. From January 2017 to December 2022, 561 patients who had undergone autologous hematopoietic stem cell mobilization and collection at Peking University Cancer Hospital were analyzed retrospectively. In the post-plerixafor era, the parameters of the mobilization and collection of stem cells have changed. Some factors still influence the number of stem cells collected, such as age, pre-apheresis blood platelet counts, peripheral blood CD34 + cells; However, the pathological type of patients, bone marrow infiltration, number of treatment lines, and whether small molecule drugs such as lenalidomide were used had no significant effect on the number of CD34 + cells collected. Although the number of CD34 + cell yields in chemo-mobilization is indeed higher than that in steady-state mobilization, clinicians also need balance benefits versus risks to select appropriate mobilization regimens. Plerixafor as a new mobilizer can improve the results of CD34 + cell yields, with cost-effectiveness being taken into account.